Patent Application Titled "Minimal Motifs of Linear B-Cell Epitopes in L1 Protein from Human Papillomavirus Type 58 and Their Applications" Published Online
The assignee for this patent application, patent application serial number 364952, is
Reporters obtained the following quote from the background information supplied by the inventors: "Chemical synthesized peptides were expected to be the third milestone, following inactivated virus vaccines and virus subunit vaccines, in the history of human vaccine development. However, none of preventative or therapeutic synthetic peptide vaccines comprising one or two epitopes (epitope is the part of an antigen that is recognized by the immune system, specifically by antibodies and B cells. See the definition in the DETAILED DESCRIPTION OF THE INVENTION) have been approved for clinical applications since 1970s due to the lack of sufficient and efficient immune effects against viruses. Therefore, in order to achieve sufficient and efficient preventive effects against viruses for clinical applications, synthetic peptide vaccines should combine more linear B-cell epitopes if possible (multi-epitope peptide immunogen can be prepared with bioengineering). In addition, single-epitope peptides consisting of 12.about.20 amino acids are usually used as antigen reagents to detect serum antibodies for the diagnosis of virus infections because natural virus proteins are usually unavailable.
"It has been known that a linear B-cell epitope usually consists of 3.about.8 amino acids. Therefore, it is obvious that using a longer peptide as testing antigen could have problems because it might contain additional epitopes that are recognized by specific antibodies among thousands of antibodies that are present in normal human serum, resulting in high false positive detection rates. In order to improve the specificity and sensitivity of the epitope peptide antigens in diagnosing virus infections and autoimmune diseases, a new trend has been to use short epitope peptides based on minimal motifs, and/or to develop a multi-epitope peptide antigen comprising as many precise epitope motifs as possible on a specific target antigen protein. The former strategy could avoid false positive results, and the rafter will improve detection sensitivity since multiple epitopes in a target protein would be recognized by more antibodies, and this strategy is particularly useful for detecting lower antibody titers elicited by viral infections or autoimmune diseases.
Most Popular Stories
- Bipartisan Budget Deal Gets Key Support in House
- TFA Recruiting DACA Recipients
- Bitcoin Clones Lurch Onto Financial Scene
- Clinton to Keynote Annual Simmons Leadership Conference
- Scotch Whisky Sales Raise Distillers' Spirits
- Holiday Shopping Off to a Slow Start This Season
- Fake Deaf Interpreter Was Hallucinating, Has Schizophrenia
- Health Coverage Disparities Emerge Among States
- Podesta Likely to Reject Keystone XL
- Tea Party Glum in Face of Bipartisan Budget Deal